IN THE CLAIMS:

Please cancel claims 24 and 32 without prejudice or disclaimer and amend claims 15, 22, 25-29, and 33-34 as follows:

15. (Twice Amended) An antibody which binds to a nuclear matrix protein, or a fragment thereof, selected from the group consisting of:

(a) RCCA-1 having a molecular weight of about 53 kD and a pI of about 9.30;

(b) RCCA-2 having a molecular weight of about 32 kD and a pI of about 6.95;

(c) RCCA-3 having a molecular weight of about 27 kD and a pI of about 6.50;

(d) RCCA-4 having a molecular weight of about 20 kD and a pI of about 5.25;

(e) RCCA-5 having a molecular weight of about 15 kD and a pI of about 6.00; and

(f) RCNL-1 having a molecular weight of about 103 kD and a pI of about 8.30, said nuclear matrix protein is present in normal renal cells but absent in cancerous renal cells, or absent in normal renal cells but present in cancerous renal cells.

22. (Twice amended) A method for detecting a cell proliferative disorder in a subject, comprising contacting a cellular component from the subject with said antibody of claim 15, which binds to a cellular component associated with a cell proliferative disorder, and detecting whether or not the antibody binds to the cellular component.

25. (Amended) The method of claim 22, wherein said antibody is polyclonal.

26. (Amended) The method of claim 22, wherein said antibody is monoclonal.

27. (Amended) The method of claim 22, wherein said antibody is detectably labeled.

28. (Amended) The method of claim 27, wherein said label is selected from the group consisting of a radioisotope, a bioluminescent compound, a chemiluminescent compound, a fluorescent compound, a metal chelate, and an enzyme.

29. (Amended) A method of treating a cell proliferative disorder associated with a renal matrix protein selected from the group consisting of RCCA-1, RCCA-2, RCCA-3, RCCA-4, RCCA-5, RCNL-1, comprising administering to a subject with said disorder a therapeutically effective amount of said antibody of claim 15, which blocks or enhances the function of said renal matrix protein.

33. (Amended) The method of claim 29, wherein said antibody is monoclonal.

34. (Amended) The method of claim 29, wherein said antibody is polyclonal.

In addition, please add the following new claims:

48. (New) The method of claim 22, wherein said cellular component is taken from the subject's kidney.

49. (New) The method of claim 22, wherein said cellular component is a protein.